EP 2310366 A2 20110420 - NOVEL TRIAZOLO(4,3-A)PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
Title (en)
NOVEL TRIAZOLO(4,3-A)PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
Title (de)
NEUE TRIAZOLO(4,3-A)PYRIDINDERIVATE, VERFAHREN ZU DEREN HERSTELLUNG, DEREN VERWENDUNG ALS MEDIKAMENTE, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND NEUE ANWENDUNG, INSBESONDERE ALS MET-INHIBITOREN
Title (fr)
NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
Publication
Application
Priority
- FR 2009051406 W 20090716
- FR 0804084 A 20080718
- FR 0900245 A 20090121
Abstract (en)
[origin: WO2010007316A2] The invention relates to the novel products of formula (I): in which: Ra represents H, Hal, aryl or heteroaryl, which is optionally substituted; Rb represents H, Rc, -COORc-CO-Rc or -CO-NRcRd; where Rc represents alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, all optionally substituted; Rd represents H, alk or cycloalkyl; these products being in all the isomer forms and the salts, as medicaments, in particular as MET inhibitors.
IPC 8 full level
C07D 213/02 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61P 3/00 (2006.01); A61P 7/02 (2006.01); A61P 11/06 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 27/00 (2006.01); A61P 35/00 (2006.01); A61P 37/08 (2006.01); C07D 213/26 (2006.01); C07D 213/61 (2006.01); C07D 249/12 (2006.01); C07D 277/82 (2006.01); C07D 471/04 (2006.01)
CPC (source: EP KR US)
A61K 31/428 (2013.01 - EP US); A61K 31/437 (2013.01 - EP KR US); A61K 31/496 (2013.01 - EP US); A61K 31/5377 (2013.01 - EP US); A61P 3/00 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 7/02 (2017.12 - EP); A61P 7/04 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 27/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 35/04 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 417/12 (2013.01 - KR); C07D 471/04 (2013.01 - EP KR US)
Citation (search report)
See references of WO 2010007316A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated extension state (EPC)
AL BA RS
DOCDB simple family (publication)
WO 2010007316 A2 20100121; WO 2010007316 A3 20100429; AR 072819 A1 20100922; AU 2009272516 A1 20100121; BR PI0916464 A2 20180612; CA 2730959 A1 20100121; CL 2011000119 A1 20110617; CN 102159543 A 20110817; CO 6331463 A2 20111020; EA 201170222 A1 20110830; EP 2310366 A2 20110420; IL 210688 A0 20110331; JP 2011528337 A 20111117; KR 20110039558 A 20110419; MA 32570 B1 20110801; MX 2011000671 A 20110411; PE 20110560 A1 20110829; TW 201008938 A 20100301; US 2011263594 A1 20111027; UY 31996 A 20100226
DOCDB simple family (application)
FR 2009051406 W 20090716; AR P090102727 A 20090717; AU 2009272516 A 20090716; BR PI0916464 A 20090716; CA 2730959 A 20090716; CL 2011000119 A 20110118; CN 200980136539 A 20090716; CO 11004610 A 20110118; EA 201170222 A 20090716; EP 09736253 A 20090716; IL 21068811 A 20110116; JP 2011517978 A 20090716; KR 20117003697 A 20090716; MA 33625 A 20110215; MX 2011000671 A 20090716; PE 2011000048 A 20090716; TW 98124130 A 20090716; US 200913054663 A 20090716; UY 31996 A 20090717